Resverlogix Corp. (TSE:RVX)’s share price was up 12.7% during mid-day trading on Wednesday . The stock traded as high as C$3.70 and last traded at C$3.54. Approximately 245,764 shares changed hands during trading, an increase of 461% from the average daily volume of 43,790 shares. The stock had previously closed at C$3.14.
The company has a market cap of $644.37 million and a PE ratio of -4.97.
Resverlogix (TSE:RVX) last announced its quarterly earnings data on Thursday, December 13th. The biotechnology company reported C($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.08) by C($0.20). As a group, sell-side analysts expect that Resverlogix Corp. will post -0.280000010980393 EPS for the current year.
WARNING: “Resverlogix (RVX) Trading Up 12.7%” was first posted by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://dakotafinancialnews.com/2019/03/15/resverlogix-rvx-trading-up-12-7.html.
Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in Phase III clinical trials for the treatment of patients with cardiovascular diseases, diabetes mellitus, chronic kidney diseases, renal diseases, peripheral artery diseases, orphan diseases, and neurodegenerative diseases.
Further Reading: What is Call Option Volume?
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.